


DT03 Rec'd PCT/PTO 28 JAN 2005 PCT #2



PATENT
ATTORNEY DOCKET NO.: 056291-5177

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)
NEWCOMBE et al.)
Application No.: 10/507,162) Group Art Unit:
Filed: September 9, 2004) Examiner:
FOR: PYRIMIDINE COMPOUNDS)

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop __
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: January 28, 2005

INFORMATION DISCLOSURE STATEMENT

Sir:

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Examiner's Initials	Inventor	U.S. Serial No. U.S. Filing Date	U.S. Patent No. Issued:	PCT Publication No. PCT Publication Date
	Breault et al.	09/763,705 02/26/2001		WO 00/12485 Mar 9, 2000
	Breault et al.	10/771,118 02/04/2004		WO 00/12485 Mar 9, 2000
	Breault et al.	09/763,681 02/26/2001	6,632,820 10/14/2003	WO 00/12486 March 9, 2000
	Bradbury et al.	09/868,602 06/20/2001	6,593,326 07/15/2003	WO 00/39101 July 6, 2000
	Breault et al.	09/914,788 09/05/2001	6,716,831 04/06/2004	WO 00/53595 Sept. 14, 2000
	Breault	09/958,077 10/04/2001	6,670,368 12/30/2003	WO 00/59892 Oct. 12, 2000

Examiner's Initials	Inventor	U.S. Serial No. U.S. Filing Date	U.S. Patent No. Issued:	PCT Publication No. PCT Publication Date
	Pease et al.	10/203,154 08/06/2002	6,649,608 11/18/2003	WO 01/64655 Sept. 7, 2001
	Pease et al.	10/220,139 08/28/2002		WO 01/64654 Sept. 7, 2001
	Pease et al.	10/203,025 08/05/2005	6,838,464 01/04/2005	WO 01/64656 Sept. 7, 2001
	Pease et al.	10/995,931 11/24/2004		WO 01/64656 Sept. 7, 2001
	Pease et al.	10/203,549 08/08/02	6,710,052 03/23/2004	WO 01/64653 Sept. 7, 2001
	Pease et al.	10/753,959 01/09/2004		WO 01/64653 Sept. 7, 2001
	Thomas et al.	10/069,019 02/21/2002		WO 01/14375 A1 March 1, 2001
	Thomas	10/239,790 09/25/2002		WO 01/72717 Oct. 4, 2001
	Thomas et al.	10/332,275 01/07/2003	Allowed 10/08/2004	WO 01/04429 Jan. 17, 2002
	Breault et al.	10/363,655 03/04/2003		WO 02/20512 Mar. 14, 2002
	Thomas	10/467,886 08/13/2003	Allowed 08/10/2004	WO 02/066481 A1 Aug. 29, 2002
	Newcombe	10/479,041 11/26/2003		WO 02/096887 A1 Dec. 5, 2002
	Newcombe et al.	10/507,081 09/09/2004		WO 03/076436 A1 Sept. 18, 2003
	Newcombe et al.	10/507,169 09/09/2004		WO 03/076434 A1 Sept. 18, 2003
	Newcombe et al.	10/507,163 09/09/2004		WO 03/076433 A1

A copy of the specification and claims for each application, in the form of the published PCT application from which such application was filed, has previously been provided or is being filed herewith. Copies of the U.S. patent documents are not enclosed.

Each published document has previously been cited or is listed on the accompanying Form PTO-1449 for printing on the issued patent.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed foreign patent documents. Copies of the U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5177 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP


Date: January 28, 2005
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk

By:



Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 056291-5177	Client Ref.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: NEWCOMBE et al.	
		Appln. No.: 10/507,162	
		Filing Date: September 9, 2004	
Date: January 28, 2005		Examiner: Unassigned	Group Art Unit: Unassigned



U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	DR	2,231,765	09/1998	Canada	Geisen				
	ER	0 379 806 B1	08/1990	EPA	Tomino et al.				
	FR								
	GR								
	HR								
	IR								
	JR								
	KR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	LR	Boschelli et al., "Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8- <i>H</i> -pyrido[2,3- <i>d</i>]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors, J. Med. Chem., Vol. 41, 1998, pp. 4365-4377				
	MR	Deady et al., "Reactions of some Quinazoline Compounds with Ethoxymethylenemalononic Acid Derivatives", J. Heterocyclic Chem., Vol. 26, 1989, pp. 161-168				
	NR	El-Kerdawy et al.; "2,4-Bis (Substituted)-5-Nitropyrimidines of Expected Diuretic Action"; Egypt J. Chem. Vol. 29, No. 2, 1986, pp. 247-251				
	OR	Fiziol Akt Veshchestva, 1975, Vol. 7, pp. 68-72		X		X
	PR	Ghosh et al.; "2,4-Bis(arylamino)-5-methylpyrimidines as Antimicrobial Agents"; J. Med. Chem., 1967, Vol. 10, No. 5, pp. 974-975;				
	QR	Ghosh, "2,4-Bis(Arylamino)-6-Methyl Pyrimidines as Antimicrobial Agents", J. Indian Chem. Soc., Vol. 58, No. 5, 1981, pp. 512-513				
	RR	Schmidt et al.; "A Convenient Synthesis of 2-substituted 4-Amino-5-pyrimidinecarbonitriles"; J. Heterocycle Chem., 1997, Vol. 24, No. 5, pp. 1305-1307				
	SR	Zimmermann et al., "Phenylamino-Pyrimidine (PAP) Derivatives: A New Class of Potent and Selective Inhibitors of Protein Kinase C (PKC), Arch. Pharm. Pharm. Med. Chem., Vol. 329, 1996, pp. 371-376				

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.